言語を選択

IL-12 R beta 1

IL-12 R beta 1 詳細

英語名	Interleukin-12 receptor	市販薬剤の数	0
治験薬の数	9	ターゲットの別称	Receptors， Interleukin-12
研究＆開発段階	Phase 2 Clinical

英語名	Interleukin-12 receptor
ターゲットの別称	Receptors， Interleukin-12
市販薬剤の数	0
治験薬の数	9
研究＆開発段階	Phase 2 Clinical

IL-12 R beta 1 製品リスト

属性
Protein (7)
製品ライブラリ
オンライン (7)
種
Human (4)Cynomolgus (2)Mouse (1)
タグ
His Tag (1)Fc Tag & Avi Tag (1)Fc Tag (2)His Tag & Avi Tag (3)
マーカー
Unconjugated (3)Biotin-labeled (4)

製品番号	種	発現システム	製品説明
HOT ILB-H5255	Human	HEK293	Human IL-12 R beta 1 / CD212 Protein, Fc Tag (MALS verified)
HOT ILB-H52E1	Human	HEK293	Biotinylated Human IL-12 R beta 1 / CD212 Protein, His,Avitag™ (MALS verified)
HOT ILB-H52H9	Human	HEK293	Human IL-12 R beta 1 / CD212 Protein, His Tag (MALS verified)
HOT ILB-H82F7	Human	HEK293	Biotinylated Human IL-12 R beta 1 / CD212 Protein, Fc,Avitag™
ILB-M52E1	Mouse	HEK293	Biotinylated Mouse IL-12 R beta 1 / CD212 Protein, His,Avitag™
ILB-C5253	Cynomolgus	HEK293	Cynomolgus IL-12 R beta 1 Protein, Fc Tag
ILB-C52E2	Cynomolgus	HEK293	Biotinylated Cynomolgus IL-12 R beta 1 / CD212 Protein, His,Avitag™

総数量7

IL-12 R beta 1バックグランド

The human IL-12 R subunit is a member of the cytokine receptor superfamily and the functional high-affinity IL-12R is composed of at least two beta-type cytokine receptor subunits, each independently exhibiting a low affinity for IL-12. IL-12 R beta 1 (Interleukin-12 receptor subunit beta-1) is also known as IL-12RB1, CD212. Functions as an interleukin receptor which binds interleukin-12 with low affinity and is involved in IL12 transduction. Associated with IL12RB2 it forms a functional, high affinity receptor for IL12. Associates also with IL23R to form the interleukin-23 receptor which functions in IL23 signal transduction probably through activation of the Jak-Stat signaling cascade.

IL-12 R beta 1分子の別称

IL-12 R beta 1,IL12RB1,CD212,IL12R,IL12RB,IL-12RB1

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
KLT-1101	KLT-1101	Phase 2 Clinical	Kang Litai Pharmaceutical Co Ltd	Leukopenia; Melanoma; Sarcoma, Kaposi; Solid tumours; Thrombocytopenia	詳細
Edodekin alfa	RO 247472; YM 01C	Phase 2 Clinical	F. Hoffmann-La Roche Ltd, Valeant, Wistar Institute	Abdominal Neoplasms; Asthma; Bacterial Infections; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Graft vs Host Disease; Hepatitis B; Hepatitis C; HIV Infections; Leishmaniasis; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Malaria; Melanoma; Neoplasms; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck	詳細
RTX-224	RTX-224	Phase 2 Clinical	Rubius Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	詳細
KB-707	KB707; KB-707	Phase 2 Clinical	Krystal Biotech Inc	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Neoplasms; Skin Melanoma; Solid tumours	詳細
ASP-9801	ASP-9801	Phase 1 Clinical	Astellas Pharma Inc	Neoplasm Metastasis; Neoplasms; Solid tumours	詳細
Tolododekin Alfa	ANK101; ANK-101	Phase 1 Clinical	Ankyra Therapeutics Inc	Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Rejection of renal transplantation; Skin Neoplasms; Soft Tissue Injuries; Solid tumours	詳細
CLN-617	CLN-617	Phase 1 Clinical	Cullinan Therapeutics Inc	Solid tumours	詳細
SON-1010	SON-1010	Phase 1 Clinical	Sonnet Biotherapeutics Inc	Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Sarcoma; Solid tumours	詳細
phIL12 GET		Phase 1 Clinical	Institute Of Oncology Ljubljana	Carcinoma, Basal Cell	詳細

レビュー

K***n2024-10-05
0評価
Biotinylated Mouse IL-12 R beta 1 / CD212 Protein, His,Avitag™
I’ve been using the IL12 receptor protein from Acro Biosystem in my antibody discovery research, and I’m highly satisfied with its quality. The protein exhibits excellent stability and bioactivity, which has been crucial in my experiments targeting immune responses. It’s been a reliable reagent, showing consistent results across various assays. I highly recommend this product for anyone involved in immunological research, particularly in therapeutic antibody development.